Wire
02:09ZWFWITNESSQatari mediators hold more than 12 hours of talks in Tehran seeking agreement, Axios reports02:08ZBBC NEWSThree dead after two helicopters collide midair near Oregon airport02:02ZPRESSTVIraqi tribal leaders pay tribute to slain Iranian leader in Mashhad02:02ZGEOPWATCHU.S. official tells Axios the best chance for an Iran agreement is now02:02ZOSINTLIVEFederal judge orders Trump Justice Department to stop threatening election officials02:01ZEPOCHTIMESHelicopter With EU Force in Bosnia Crashes01:57ZWARMONITORUS official tells Axios the best chance for Iran to reach an agreement is now01:56ZDEUTSCHE WEuropean diplomats shun Russia at G20 gathering in the US
  • S&P 500 ETF▼ 1.77%
  • Nasdaq▼ 2.86%
  • Nasdaq 100▼ 3.46%
  • Dow ETF▼ 1.07%
Terminal ↗
← The MonexusScience

A Cheap Antidepressant, a Long COVID Puzzle, and the Limits of a Single Trial

A 399-person randomized trial suggests fluvoxamine eases long COVID fatigue. The result is real, but the science behind it is messier than the headline.

A 399-person randomized trial suggests fluvoxamine eases long COVID fatigue.
A 399-person randomized trial suggests fluvoxamine eases long COVID fatigue. sciencedaily.com / Photography

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

  • https://t.me/themonexus/4df76be4a7
  • https://en.wikipedia.org/wiki/Fluvoxamine
  • https://en.wikipedia.org/wiki/Long_COVID
  • https://en.wikipedia.org/wiki/Selective_serotonin_reuptake_inhibitor
  • https://en.wikipedia.org/wiki/Randomized_controlled_trial
  • https://en.wikipedia.org/wiki/Placebo_effect
Intelligence ThreadFollow on terminal ↗
© 2026 Monexus Media · AI-native reporting from public-source material
The Monexus

Read with context.

Using this article and its related event records

Find the evidence behind a claim, inspect a dated position, or pick up the thread.

Source lookup is available to everyone. Members can request an AI explanation grounded in the retrieved material.

Browse event files →
A Cheap Antidepressant, a Long COVID Puzzle, and the Limits of a Single Trial - The Monexus